Nurtec ODT vs Aimovig
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Nurtec ODT | US Aimovig | |
|---|---|---|
| Generic name | rimegepant | erenumab |
| Drug class | CGRP Receptor Antagonist | CGRP Receptor Antagonist (Biologic) |
| Treats | Migraine (acute and preventive) | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Pfizer | Amgen/Novartis |
| Year approved | 2020 | 2018 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $190M | $100M |
| Common side effects | Nausea, Stomach pain, Indigestion, Allergic reactions | Constipation, Injection site reactions, Muscle cramps, High blood pressure |
Nurtec ODT
Frequently asked questions
Is Nurtec ODT or Aimovig better?
Neither is universally "better." Nurtec ODT (rimegepant) and Aimovig (erenumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Nurtec ODT and Aimovig?
Nurtec ODT is a CGRP Receptor Antagonist made by Pfizer, while Aimovig is a CGRP Receptor Antagonist (Biologic) made by Amgen/Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Nurtec ODT has the larger estimated TV advertising budget of the two.